ArticleFrontiers in oncology2026
Transoral plasma radiofrequency ablation for selected supraglottic and glottic laryngeal cancer: a propensity score-matched comparative study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Transoral endoscopic surgery is a preferred treatment for early-stage and selected advanced laryngeal cancers. Transoral plasma radiofrequency ablation (TPRA) has shown promise for glottic cancer, however, its efficacy in T1-T2 supraglottic and selected advanced T2-T3 glottic cancers requires further evaluation. Methods: We retrospectively compared 31 patients with T1-T2 supraglottic or T2-T3 glottic cancers treated with TPRA with 36 patients treated with open partial laryngeal surgery. Disease-specific survival (DSS), disease-free survival (DFS), and local control (LC) were analyzed using multivariable Cox proportional hazards regression. Postoperative outcomes and preservation of laryngeal function were also evaluated. Results: After propensity score matching, 67 patients were included in the analysis. The TPRA group had a shorter median hospital stay (8 days), and no patient required synchronous tracheotomy or experienced postoperative bleeding. Functional recovery was generally faster than in the open surgery group, including avoidance of routine nasogastric tube feeding. Temporary dysphagic cough (25.8%) and granulation tissue (16.1%) were observed. The 5-year DSS, DFS, and LC rates after TPRA were 77.4%, 71.0%, and 83.1%, respectively, which were comparable to those after open surgery (74.8%, 72.2%, and 84.9%, respectively; all P > 0.05). Conclusion: TPRA demonstrated oncologic efficacy comparable to open surgery for selected T1-T2 supraglottic and T2-T3 glottic cancers, with better functional preservation and fewer perioperative complications. Together with its technical adaptability, TPRA may represent a valuable treatment option for carefully selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.